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mutations in Plasmodium vivax against
sulphadoxine-pyrimethamine in southern
Pakistan
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Abstract
Background: In Pakistan, Plasmodium vivax and Plasmodium falciparum co-exist and usage of sulphadoxine-
pyrimethamine (SP) against P. falciparum exposes P. vivax to the drug leading to generation of resistant alleles. The
main aim of this study was to investigate frequency distribution of drug resistance associated mutations in pvdhfr,
pvdhps genes and provide baseline molecular epidemiological data on SP-associated resistance in P. vivax from
southern Pakistan.
Methods: From January 2008 to May 2009, a total of 150 samples were collected from patients tested slide-positive
for P. vivax, at the Aga Khan University Hospital, Karachi, or its collection units located in Baluchistan and Sindh
Province. Nested PCR using pvdhfr and pvdhps specific primers was performed for all samples.91.3% (137/150) of
the samples were tested PCR positive of which 87.3% (131/137) were successfully sequenced. Sample sequencing
data was analysed and compared against wild type reference sequences.
Results: In dhfr, mutations were observed at codons F57L, S58R and S117N/T. Novel non-synonymous mutations
were observed at codon positions N50I, G114R and E119K while a synonymous mutation was observed at codon
position 69Y. In dhps, mutations were observed at codon position A383G and A553G while novel non-synonymous
mutations were observed at codon positions S373T, E380K, P384L, N389T, V392D, T393P, D459A, M601I, A651D
and A661V.
Conclusion: This is the first report from southern Pakistan on SP resistance in clinical isolates of P. vivax. Results
from this study confirm that diverse drug resistant alleles are circulating within this region.
Keywords: Plasmodium vivax, Pakistan, Dihydrofolate reductase, Dihydroptereoate synthase, Single nucleotide
polymorphisms
Background
Plasmodium vivax malaria is an important public health
problem worldwide causing an estimated 80–215 million
clinical infections annually. Geographically, it is found
throughout Asia, South and Central America, Middle
East and some parts of Africa [1].
Malaria is endemic throughout Pakistan with an esti-
mated 4.5 million suspected cases reported by World
Health Organization [2]. Southern Pakistan, where this
study was conducted, comprises of moderate to high
malaria endemicity areas with annual parasite incidences
reported as high as 5.5/1,000 population [3] see Figure 1.
Both P. vivax and Plasmodium falciparum co-exist, with
P. vivax being the major contributor (70%) of malaria
burden in all areas [2].
In Pakistan, the treatment guidelines recommended by
National Malaria Control Programme (MCP) until 2007
was chloroquine (CQ) as the first-line and sulphadoxine-
pyrimethamine (SP) as the second-line treatment of un-
complicated P. falciparum malaria. With reports of CQ
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resistance, the treatment policy was changed in 2008, with
the combination of artesunate (AS) plus sulphadoxine-
pyrimethamine against uncomplicated P. falciparum and
chloroquine plus primaquine recommended as the first-line
treatment for P. vivax malaria, respectively [4]. Though
recommended, implementation of treatment guidelines is
non-existent with studies documenting only 1% of patients
receiving combination therapies [2,5]. Furthermore, with
co-existence of both species in significant proportions, is-
sues of misdiagnosis due to sub-microscopic infections in
association with P. falciparum [6] and inappropriate treat-
ment with mono-therapies exist in the public sector [7].
The consequence of such approach may have implications
on P. vivax control in the region since mono-therapy may
induce drug pressure on P. vivax resistance associated
genes and trigger the selection of resistant alleles. As yet,
limited data is available from Pakistan on the prevalence of
resistance in P. vivax.
Molecular and epidemiological studies conducted in
various malaria-endemic regions have shown that thera-
peutic targets of SP in both P. falciparum and P. vivax
are dihydrofolate reductase (dhfr) and dihydroptereoate
synthase (dhps) enzymes. Dhfr codons for pyrimethamine
(PYR) interaction have been identified as I13, P33, F57,
S58, T61, S117 and I173 while dhps codons S382, A383,
K512, A553 and V585 are sulphadoxine (SPX) binding co-
dons [8]. Single nucleotide polymorphism (SNP) in SPX
and PYR binding sites is the mechanism employed by
Plasmodium species to survive drug pressure and transmit
effectively. Briefly, accumulation of SNPs lead to changes
in amino acid residues at key codon positions resulting in
alteration of drug interaction sites, thus preventing drugs
binding to enzyme active sites [9,10]. Changes in amino
acid residues commonly associated with SPX and PYR re-
sistance are I13L, P33L, F57L/I, S58R, T61M, S117N/T,
I173L/F and 382A/C, 383G, 512M/T/E, 553G/C, V585
(any non-synonymous amino acid change) [8]. Further-
more, SNPs leading to insertion/deletion of amino acids in
known repeat regions of dhfr (GGDNTS/TH/ADK) and
dhps (GEAKLTN/G/A/G/A/G/GDAKLTN/S/A) result in
generation of tandem repeat variant types (TRV types).
These TRV types have been used in studies for genotyping
of dhfr and dhps alleles [11,12]. Some studies have also
suggested possible association of TRV types with mutant
alleles and disease severity [11,13,14].
Data on SP-resistant alleles have been reported from
various malaria-endemic regions, such as Thailand,
Indonesia, Papua New Guinea, Madagascar, Iran, India and
Afghanistan. However, limited studies on SP resistance and
cure rates have been documented from northern Pakistan
[6,15,16] where SP is rendered effective against P. vivax.
However, data on SP resistance from southern Pakistan is
lacking. Therefore, the aim of this study was to investigate
frequency distribution of SP resistance associated mutations
in pvdhfr and pvdhps genes in clinical isolates from south-
ern Pakistan so that baseline molecular epidemiological
data on extent of SP resistance could be documented.
Methods
Study design, settings and ethical considerations
A descriptive study to determine the prevalence of drug
resistance associated single nucleotide polymorphisms in
Karachi Rural Sindh
Baluchistan
Figure 1 Map of Pakistan showing study sites.
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P. vivax clinical isolates was carried out between January
2008 and May 2009. A total of 150 patients, presenting
with microscopy-confirmed, asexual P. vivax mono-
infection at Aga Khan University Hospital, Karachi or its
collection units located in Sindh and Baluchistan prov-
inces were enrolled in the study. The study was approved
by the Ethical Review Committee of Aga Khan University
Hospital and conducted in accordance with the Good
Clinical Practice of Declaration of Helsinki [17]. Informed
consent was obtained from enrolled patients or in case of
children from their parents/legal guardians.
Blood collection and microscopy
Approximately 2 ml of intravenous blood sample in EDTA
tube was collected. Initial presence of malaria parasites
was established by Leishman’s staining while further spe-
cies identification was determined by Giemsa staining of
thick and thin blood smears [18]. The remaining blood
was stored at -80°C until further analysis.
DNA extraction and amplification
DNA was extracted from 200 μl of whole blood using
QiAamp DNA Mini Kit according to manufacturer’s in-
structions (QIAGEN, USA). Plasmodium vivax dhfr and
dhps genes were amplified using nested PCR methodology
as described previously [19,20]. Analysis of PCR products
was done by gel electrophoresis. Briefly, amplified product
was loaded on 1.5% agarose gels alongside 100 bp molecu-
lar weight markers, separated in Tris borate (TBE) buffer
by electrophoresis, stained with ethidium bromide and vi-
sualized under UV transilluminator (Gel Doc, Bio-Rad,
Hercules, USA).
Sequencing and similarity analysis
PCR-positive amplified products of dhfr and dhps were
purified using QIA quick Qiagen PCR purification kit
(QIAGEN, USA). Direct sequencing of purified products in
both directions was performed commercially (Macrogen,
Korea). Nucleotide and amino acid sequences were com-
pared with wild type dhfr and dhps reference sequences
using pair wise sequence similarity analysis software
BLAST. Gen Bank accession numbers of wild type se-
quences used for comparison are ARI/Pakistan X98123
for dhfr and AY186730 for dhps.
Data interpretation
Samples were interpreted as wild type (WT) if no muta-
tions were observed in the entire dhfr and dhps coding
region. Single, two, three or four mutations observed ei-
ther in dhfr, dhps or both coding regions was designated
as single, double, triple and quadruple mutations re-
spectively (SM, DM, TM and QM). The dhfr and dhps
TRV types were categorized as Type A-C and Type 1a-
6a on the basis of insertion/deletion of amino acids at
the repeat codon position 88–106 of dhfr and 603–665
of dhps.
Statistical analysis
Data were entered in Microsoft Excel and exported to
SPSS version 19.0 for analysis. Arithmetical means and
medians were calculated where applicable, for all con-
tinuous baseline demographic variables. Allele propor-
tions were calculated as the number carrying a certain
allele divided by the number of samples with positive
PCR outcome.
Results
Baseline demographic data
A total of 150 patients with microscopy-confirmed P. vivax
mono-infection were enrolled from Karachi, Baluchistan
and Rural Sindh. Out of these, 137 (91.3%) were PCR
positive for both dhfr and dhps and were thus selected
for sequencing. Sequencing was successful in 131 (87.3%)
samples of which 98 were from Karachi, 13 from Baluchi-
stan and 20 from Rural Sindh.
Distribution of pvdhfr and pvdhps mutations
Sequence analysis revealed mutations in dhfr codons
F57L, S58R and S117N/T while no mutation was ob-
served at P33, T61 and I173. Novel non-synonymous mu-
tations were observed at codon positions N50I, G114R
and E119K while synonymous mutation was observed at
codon position 69Y. In dhps, mutations at the SPX bind-
ing sites was observed at codon position A383G and
A553G while non-synonymous mutations were observed
at codon positions S373T, E380K, P384L, N389T, V392D,
T393P, D459A, M601I, A651D and A661V.
Haplotyping analysis revealed identification of nine
pvdhfr-pvdhps types in the study areas (Table 1). Of
these, pure WT isolates were observed in 38.9% (51/131)
of the total isolates and in all the three sampling sites.
Single mutation in dhfr was observed in 19.8% of the
total isolates at codon position 58R and 117N, respect-
ively. Of these, 58R were detected in Karachi isolates
only while 117N was observed in all sampling sites in
frequencies of 17.3% (Karachi), 15% (Sindh) and 30.8%
(Baluchistan), respectively. Double mutation in dhfr was
observed in 27.4% of the total isolates in a combination
of 58R/ 117N/T and 57L/ 58R, respectively. Of these,
58R/ 117N/T were found to be the frequently isolated
DM in all the study sites (25.2%). DM 57L/ 58R was ob-
served in Karachi and Sindh only.
In dhps, single mutant 383G was observed in frequen-
cies of 7.4 and 10% in Karachi and rural Sindh respect-
ively. Double, triple and quadruple alleles in combination
with dhfr alleles (117N/T/383G, 58R/117N/T/383G, 58R/
117N/T/3838G/553G) were observed. DM and TM were
observed in low frequencies and were isolated from
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Karachi only while QM was observed in one isolate from
Baluchistan.
Of the other non-synonymous mutations in dhfr, SM
was observed in 114R and 119K. DM was observed in
combination of 50I/119K, 114R/119K, 119K/117N and
50I/117N. DM found predominantly in all the sampling
sites was 50I/117N observed in proportions of 5.1% in
Karachi, 7.7% in Baluchistan and 15% in Sindh. All other
mutant alleles, including distinctive 117T, were observed
infrequently in the three sampling areas.
Other non-synonomous mutations observed in dhps
were S373T, E380K, P384L, N389T, V392D, T393P,
D459A, M601I, A651D and A661V. Of these, with the
exception of 373T, 601I, 651D and 661V, all other were
observed in Karachi only while these mutant alleles were
observed in low frequencies in all the sampling sites.
Distribution of pvdhfr and pvdhps tandem repeat variant
types
TRV types were classified as Type A-C based on dele-
tion/insertion of six amino acids at codon position 88–
106 (Table 2). Type B was found to be the predominant
TRV with 94.6% (124/131) of the isolates from all sam-
pling sites exhibiting this type. Type A and C were ob-
served in 3.8% and 1.5% of the isolates from Karachi
only (Table 3). Type B was found to be commonly asso-
ciated with WT, single and double dhfr (117N/T and
58R/117N/T) while Type A and C were associated with
wild type alleles.
In dhps, six TRV types, designated as Type 1–6 and
sub-typed as a, b, c, and d, were identified and catego-
rized depending on the insertion and deletion of amino
acids at various codon positions in the repeat region
(Table 4). Type 3 (subtype 3a) consisting of seven tan-
dem repeats and amino acids deleted at codon positions
631–644 was found to be the predominant with 51.9%
of the isolates from all study sites exhibiting this type
(Table 5). This type was found to be associated with
WT, SM, DM, TM and QM haplotypes. Distinct type 6
comprising of 11 repeats was observed in three isolates
and was found associated with TM alleles.
Single mutation at codon position 661V and 651D in
repeat region resulted in generation of novel repeat types
1b, 2d and 3c, respectively. TRV Type 1a, 2b, 3a, 3c, 5a
was observed in all sampling sites. Type 4c in Baluchistan
and Type 2a, 2c, 2d, 4a, 4b and 6a were observed exclu-
sively in Baluchistan and Karachi isolates only.
Discussion
This is the first study to provide baseline molecular epi-
demiological data on prevalence of SP resistance associ-
ated SNPs in P. vivax clinical isolates from southern
Pakistan. In dhfr, wild type, single and double mutant al-
leles were observed in frequencies of 38.9, 19.8 and
27.4% respectively, indicating that wild type and double
mutants are prevalent in this region. At PYR interaction
site, 117N and 58R were found to be prevalent, both as
a single mutant as well as in combination with other
non-synonymous mutations while 57L mutation was
detected in combination with 58R in low frequency
(2.29%). These findings are similar to those reported
from Khyber Pukhtunkhwa (KPK) and Bannu district of
Pakistan [6,15], India [11-13,21], Iran [22], Afghanistan
[14], China [23], Madagascar [24], East Timor [25],
Thailand [19,26-28], Indonesia [29,30] and Mauritania [8].
Table 1 Frequency distribution of pvdhfr-pvdhps haplotypes in P. vivax isolates from southern Pakistan
pvdhfr-pvdhps haplotypes Mutations Karachi Sindh Baluchistan Total (%)
IPFSTSI-AA 0 40 (40.8) 8 (40.0) 3 (23.1) 51 (38.9)
IPFSTN/TI-AA 1 17 (17.3) 3 (15.0) 4 (30.8) 24 (18.3)
IPFRTSI-AA 1 2 (2.04) - - 2 (1.53)
IPFSTSI-GA 1 7 (7.14) 2 (10.0) - 9 (6.87)
IPFRTN/TI -AA 2 23 (23.5) 5 (25.0) 5 (38.5) 33 (25.2)
IPLRTSI-AA 2 2 (2.04) 1 (18.9) - 3 (2.29)
IPFSTN/TI-GA 2 3 (3.06) - - 3 (2.29)
IPFRTN/TI-GA 3 1 (1.02) - - 1 (0.76)
IPFRTN/TI-GG 4 - - 1 (7.7) 1 (0.76)
pvdhfr: I13L ,P33L,F57L,S58R,T61M,S117N/T,I173L.
pvdhps: A383G,A553G.
Bold face represents change in amino acid.
Table 2 Tandem repeat variants types of dhfr
Types No. of
repeats
Amino acid polymorphisms (Insertions/
deletions)
A 4 GGDNTS GGDNTH GGDNTH GGDNAD
B 3 GGDNTS GGDNTH GGDNAD
C 2 ———— GGDNTH GGDNAD
Underline represents insertion and -——— represents deletion of amino acid
residues at the respective codon position.
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The dhfr resistance patterns, commonly observed world-
wide, of primary accumulation of mutations in codon 117
and 58 followed by amino acid change in codon 57 [19]
was also observed in both northern and southern
Pakistan, indicating a progressive tolerance in P. vivax to
SP. In vitro studies have shown that compared to wild type
enzymes, 58R, 117N and 57L mutant enzymes show ap-
proximately 1.9 to >500-fold increase in IC50 when tested
against PYR and chlorcycloguanil [29,31]. Corroboration
of this finding with clinical data has also shown associ-
ation of these mutations with treatment failure cases
[24,30]. Therefore, findings from this study indicate that
in Pakistan, SP used for P. falciparum infection is selecting
SP mutant alleles in P. vivax isolates. Consequently, exten-
sive transmission of these resistant alleles within the
population may affect SP usage for Plasmodium species in
this region.
A distinctive finding, with respect to Pakistan, was the
detection of serine to threonine (S-T) mutation at 117
codon position. This mutation has not previously been
reported from other areas of Pakistan [6,15]. Globally,
117T substitution has been reported in areas of high
Table 3 Distribution of dhfr tandem repeat types in pvdhfr-pvdhps haplotypes
Types pvdhfr pvdhps Total
I13L P33L F57L S58R T61M S117N/T I173L A383G A553G n = 131 (%)
A I P F S T S I A A 4 (3.05)
I P F S T N/T I A A 1 (0.76)
B I P F S T S I A A 45 (34.3)
I P F S T N/T I A A 23 (17.5)
I P F R T S I A A 2 (1.52)
I P F R T N/T I A A 33 (25.2)
I P L R T S I A A 3 (2.32)
I P F S T S I G A 9 (6.87)
I P F R T S I G A 1 (0.76)
I P F S T N/T I G A 3 (2.32)
I P F R T N/T I G A 4 (3.05)
I P F R T N/T I G G 1 (0.76)
C I P F S T S I A A 2 (1.52)
Table 4 Tandem repeat variant types in dhps
Types No. of repeats Amino acid polymorphisms
(Insertions/deletions)
1a 5 GEAKLTN GEGKLTN ————— ————— —————————— GDAKLTN GDSKLTN GEAKLTN
1b 5 GEAKLTN GEGKLTN ————— ————— ————— ————— GDAKLTN GDSKLTN GEVKLTNK
2a 6 GEAKLTN GEGKLTN GEAKLTN GEGKLTN ————— ————— ————— GDSKLTN GEAKLTN
2b 6 GEAKLTN GEGKLTN GEAKLTN GEGKLTN ————— ————— GDAKLTN————— GEAKLTN
2c 6 GEAKLTN GEGKLTN GEAKLTN GEGKLTN ————— ————— GDAKLTN GDSKLTN —————
2d 6 GEAKLTN ————— GEAKLTN GEGKLTN ————— ————— GDAKLTN GDSKLTN GEVKLTN
3a 7 GEAKLTN GEGKLTN GEAKLTN GEGKLTN ————— ————— GDAKLTN GDSKLTN GEAKLTN
3b 7 GEAKLTN GEGKLTN GEAKLTN GEGKLTN GEAKLTN ————— ————— GDSKLTN GEAKLTN
3c 7 GEAKLTN GEGKLTN GEAKLTN GEGKLTN ———— ———— GDAKLTD GDSKLTN GEAKLTN
4a 8 GEAKLTN GEGKLTN GEAKLTN GEGKLTN GEAKLTN GEGKLTN GDAKLTN ————— GEAKLTN
4b 8 GEAKLTN GEGKLTN GEAKLTN GEGKLTN GEAKLTN GEGKLTN GDAKLTN GDSKLTN —————
4c 8 GEAKLTN GEGKLTN GEAKLTN GEGKLTN ———— ———— GDAKLTN GDSKLTN GDSKLTN GEAKLTN
5a 9 GEAKLTN GEGKLTN GEAKLTN GEGKLTN GEAKLTN GEGKLTN GDAKLTN GDSKLTN GEAKLTN
6a 11 GEAKLTN GEGKLTN GEAKLTN GEGKLTN GEAKLTN GEGKLTN GEAKLTN GEGKLTN GDAKLTN GDSKLTN GEAKLTN
Bold face represents a novel substitution of amino acid residue at the designated codon position.
Underline represents insertion and -——— represents deletion of amino acid residues at the respective codon position.
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transmission intensity and SP pressure, such as MaeSot
Thailand [27], Myanmar [32], Vietnam [33], Indonesia
[30], India [11,12]. Studies have shown that similar to
58R,117N and 57L mutation, presence of 117T mutation
also increases IC50 of yeast expression system ~40 and
~43-fold. Sequential addition of non-synonymous muta-
tions further increases the IC50 as high as >500-fold com-
pared to WT [29,31]. Clinically, patients exhibiting 117T
allele have also been found to be highly resistant to SP
treatment [30]. Thus, this mutation is associated signifi-
cantly with extensive drug resistance and high SP pressure
in an area. In this study, 117T allele was isolated from
Karachi as a double and quadruple mutant in combination
of 58R/117T, 117T/119K and 58R/117T/114R/119K
indicating that P. vivax isolates in this area may be exposed
to SP pressure, resulting in selection of dhfr alleles associ-
ated with treatment failure. Though observed in low fre-
quency, natural positive selection of this mutation requires
serious consideration as this may have significant impact
on SP treatment in this area.
Another unique finding in this study was the detection
of 50I allele, which is being reported for the first time in
southern Pakistan. Sequencing analysis of the respective
allele resulted in the retrieval of two sequences from
Pakistan exhibiting similar mutation (accession number
JN 794518 and JN 794520). This finding may be signifi-
cant since presence of 50I, reconfirmed in isolates from
other areas of Pakistan, corroborates findings from this
Table 5 Distribution of dhps tandem repeat types in pvdhfr-pvdhps haplotypes
Types pvdhfr pvdhps Total
13IL P33L F57L S58R T61M S117N/T I173L A383G A553G n = 131 (%)
1 I P F S T S I A A
I P F S T N/T I A A 20 (15.3)
I P F R T N/T I A A
I P F S T S I G A
2 I P F S T S I A A
I P F S T N/T I A A
I P F R T S I A A
I P F R T N/T I A A
I P L R T S I A A 23 (17.6)
I P F S T S I G A
I P F S T N/T I G A
I P F R T N/T I G A
3 I P F S T S I A A
I P F S T N/T I A A
I P F R T N/T I A A
I P L R T S I A A
I P F S T S I G A
I P F S T N/T I G A 68 (51.9)
I P F R T N/T I G A
I P F R T N/T I G G
4 I P F S T N/T I A A 3 (2.3)
I P F R T N/T I A A
5 I P F S T S I A A
I P F S T N/T I A A
I P F R T S I A A
I P F R T N/T I A A 14 (10.7)
I P F S T S I G A
I P F R T S I G A
6 I P F S T N/T I A A 3 (2.3)
I P F R T N/T I G A
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study. The significance of this mutation is that codon
N50 in P. vivax WT corresponds with N51 codon of P.
falciparum WT dhfr domain [31]. Previous studies, car-
ried out via detection of drug-resistant alleles and
in vitro culturing in P. falciparum, have reported that
mutation in codon 51 from asparagine-isoleucine (N-I),
in combination with other non-synonymous mutations,
particularly 108N, is associated with high-level PYR re-
sistance [12,34]. Studies on similar amino acid change in
P. vivax, N50I, in combination with 117N allele (equiva-
lent to 108N in P. falciparum) have been shown to
increase the IC50 of yeast expression system up to ~57-
fold [31]. Therefore, presence of this particular allele in
Pakistan indicates that P. vivax isolates are selecting dis-
tinct alleles that may have a role in drug resistance.
However, the effect of this mutation on drug resistance
could only be assessed by in vitro culturing or in silico
using homology modelling and molecular docking. Data
from this study was not analysed using these tools and
therefore significance of this mutation in drug resistance
cannot be commented upon.
Non-synonymous mutations 114R, 119K and syn-
onymous mutation, 69Y was predominantly, observed in
Karachi samples. The 69Y mutation has been reported
from high transmission areas of India [11,13] and there-
fore indicates natural selection of this allele in two
neighbouring countries. However, since it is a synonym-
ous mutation, its role in drug resistance is not implied.
In dhps, 383G and 553G alleles were observed in com-
bination with dhfr 117N/T and 58R alleles. The result
for 383G is in accordance with published data from
India [11], Thailand [27], Madagascar [24], Pakistan [6]
and Afghanistan [14]. However, the 553G haplotypes is
being reported for the first time from Pakistan. Previ-
ously, this combination has been reported from high
transmission area of India [11]. However, since this mu-
tant allele was observed in low frequency in this study,
analysis with respect to transmission is not possible.
Ten non-synonymous mutations were also observed in
dhps, either alone or in combination with 383G. Of
these, 459A and 601I has been reported from India [13].
Homology modelling and drug docking analysis in
Indian isolates showed no apparent change in the effi-
cacy of drug binding due to the presence of these muta-
tions. Though, this conclusion could be extrapolated for
this study’s samples, the difference is the occurrence of
these mutations in combination with 383G and other
non-synonymous mutations. Furthermore, a majority of
these mutations was observed near the SPX interaction
site (373T, 380K, 389T, 392D, 393P) and, therefore, the
combined effect of these mutations on drug binding needs
to be analysed before any conclusion can be drawn.
Non-synonymous mutations at 651D and 661V have
been observed for the first time in isolates from Pakistan.
Since these mutations were falling in the repeat region,
novel TRV types were generated (Table 4). Mutations in
the repeat regions are thought to have little impact on
drug binding, therefore their role in drug susceptibility
could be ruled out.
The high diversity observed in dhps in Pakistan is a
matter of concern with respect to SP usage. However,
an additional factor that may be influencing the selec-
tion of dhps resistant alleles is use of co-trimethoxazole
(Trimethoprim + Sulphamethoxazole). This drug is com-
monly used in Pakistan for the treatment of bacterial in-
fections or for prophylaxis and, therefore, sulpha drug
pressure intrinsically exists in the environment [16]. In
P. falciparum, complete cross resistance has been reported
among sulpha drugs with variety of dhps genotypes
[35,36]. It is possible that similar cross-resistance may be
influencing the selection of resistant alleles by exerting
pressure on P. vivax genes.
Studies have shown that TRV observed in both dhfr and
dhps can be clustered as genotypes according to their dis-
tribution in a particular area [11]. TRV Type B in dhfr and
Type 3a in dhps would thus be considered as prevalent ge-
notypes in southern Pakistan. TRV Type 6a, having 11 re-
peats was observed in three patients from Karachi, all
exhibiting severe disease symptoms. Similar finding was
reported from India [13] and it could be assumed, though
preliminarily, that Type 6a may be influencing the im-
munological response during vivax infection, possibly
leading to disease severity. However, since this is novel
data, based on sequencing only, serological studies need to
be conducted before association between TRV types and
disease severity can be implied.
Analysis of TRV association with mutation revealed
that the predominant Type B and Type 3a were com-
monly associated with both WT and mutant alleles.
These observations speculate that dhfr and dhps mutant
alleles carrying the respective tandem repeat variant
types could be susceptible to development of SP resist-
ance associated mutations. Usefulness of tandem repeat
variant types as molecular markers to predict the risk of
resistance development has been implied in some studies
[11,14], and in vitro studies would be able to provide a
better understanding of the respective association and
their impact on infection dynamics.
The results from this study show that diverse drug-
resistant alleles of P. vivax are circulating in southern
Pakistan especially in Karachi. Karachi is the largest and
most populous metropolitan city of Pakistan with a
population of 23.5 million [37]. Being a financial hub of
Pakistan, extensive human movement is common in this
area. Furthermore, during recent years, disaster induced
displacement of individuals due to conflicts in northern
Pakistan, floods and earthquakes have resulted in an in-
creased net influx of migrants in Karachi [38]. This
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migration pattern is significant as malaria is spread by
humans and this is particularly true for P. vivax, since
hypnozoite acquired in one region could relapse months
or years afterwards in a completely different place. It is
possible that this large ongoing net influx of migrants
may serve as parasite reservoirs carrying genetically
diverse and drug resistant strains of P. vivax thus
impacting malaria transmission in this area.
It is underlined that the aim of the study was to pro-
vide molecular epidemiological data on frequency distri-
bution of pvdhfr-pvdhps haplotypes so that data on
prevalent SP resistant alleles could be reported. Neither
outcomes nor quantification of SP pressure was mea-
sured in this study and data interpretation was based on
in vitro or findings reported in earlier studies on P. vivax
isolates from other geographic areas. However, similarity
of these results with those reported from other countries
allows a generalized observation that SP pressure due to
co-existence of P. falciparum exists in southern Pakistan,
resulting in selection of common and distinct SP resist-
ant alleles in P. vivax.
Conclusion
The results indicate that in southern Pakistan P. vivax
isolates are under natural selective pressure to accumu-
late SP resistance associated mutations. Therefore, ur-
gent steps are required to monitor surveillance of drug
resistance in Pakistan by concerned authorities.
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